Richard Ammer, born in Munich in 1970, is a medical doctor and business economist and has been responsible for new business development at MEDICE since 2003, including research & development, production and international marketing. He initiated a sustainable waste separation concept for Munich's household waste as a student representative during his high school days - interested in qualitative growth. After studying medicine in Munich (TU, 1990-95), Beijing (1992) and Boston (HMS, 1995/96) with scholarships from the Hanns Seidl Foundation and the DAAD, among others, and clinical and scientific training at Harvard Medical School, Massachusetts General Hospital (1996-2000) with a scholarship from the DFG, he continued his training as an internist at the German Heart Center in Munich (2000-2001) and the University Hospital in Münster (since 2001).
He was awarded the Young Investigator Award in Basic Science 2001 (Stockholm) by the European Society of Cardiology (ESC) for his research work on atrial fibrillation, for which he also received his doctorate. He was coordinator/managing director of the BMBF Competence Network for Atrial Fibrillation (Central University Hospital Münster) from 2002-05 and has been working for 20 years at the University Hospital Münster in internal medicine in patient care and academic teaching, even today in part-time employment (dialysis, kidney transplant aftercare, anemia management). He studied business administration parallel to his medical studies at the University of St. Gallen (with an interest in clinic management) and the Harvard Extension School and finally at the University of St. Gallen, where he completed his doctorate and PhD. He has also been a lecturer at the University of St. Gallen for 20 years, supervising Bachelor's, Master's and doctoral students, particularly in the field of life sciences. In 2003, Dr. Richard Ammer joined MEDICE as Managing Director in order to continue the family tradition together with his wife, but also to react proactively to the 2004 healthcare reform (GMG) with its challenges, especially for medium-sized pharmaceutical companies.
At association level, Dr. Richard Ammer has been Deputy Chairman of the Board of the German Pharmaceutical Industry Association (BPI e.V.) since 2008, where he works to unite the individual associations and raise the profile of research and production in Germany and Europe.
&nsbp;
